| __timestamp | Halozyme Therapeutics, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 16606000 |
| Thursday, January 1, 2015 | 29245000 | 21497000 |
| Friday, January 1, 2016 | 33206000 | 25462000 |
| Sunday, January 1, 2017 | 31152000 | 28195000 |
| Monday, January 1, 2018 | 10136000 | 33078000 |
| Tuesday, January 1, 2019 | 45546000 | 36523000 |
| Wednesday, January 1, 2020 | 43367000 | 41455000 |
| Friday, January 1, 2021 | 81413000 | 74400000 |
| Saturday, January 1, 2022 | 139304000 | 101582000 |
| Sunday, January 1, 2023 | 192361000 | 112903000 |
| Monday, January 1, 2024 | 159417000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of key players is crucial. This analysis delves into the cost structures of Halozyme Therapeutics, Inc. and Veracyte, Inc. over the past decade. From 2014 to 2023, Halozyme's cost of revenue surged by an impressive 747%, peaking at $192 million in 2023. In contrast, Veracyte's expenses grew by 580%, reaching $113 million in the same year. Notably, both companies experienced significant growth in 2021, with Halozyme's costs increasing by 88% and Veracyte's by 80% compared to the previous year. This trend highlights the increasing operational demands and investments in innovation within the biotech sector. As these companies continue to expand, stakeholders must keep a keen eye on their financial strategies to gauge future performance.
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Veracyte, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Veracyte, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Research and Development Investment: Halozyme Therapeutics, Inc. vs Veracyte, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.